Table 1.
Participant Characteristics
| Participant | Sex | Age, y, Time Point 2 | Time Before Initiation of Therapy, mo | CD4 Nadir | Years Between Time Points | Leukapheresis 1, Time Point 1 | Leukapheresis 2, Time Point 2 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Length of Viral Suppression, y | Treatment Regimen | CD4+ T-Cell Count | Viral Load, Copies/mL | Cells Available | Length of Viral Suppression, y | Treatment Regimen | CD4+ T-Cell Count | Viral Load, Copies/mL | Cells Available | ||||||
| 2026 | M | 63 | >12 | 132 | 3.7 | 13.2 | TDF, ABC/3TC, RTV, DRV | 476 | <40 | Naive, CM, TM, EM, HLA-DR+, HLA-DR− | 16.9 | ABC/TCV/3TC | 414 | <40 | Naive, CM/HLA-DR±, TM/ HLA-DR±, EM/HLA-DR± |
| 2046 | M | 53 | >12 | 10 | 2.8 | 15.8 | ECV, EFV/TDF/FTC | 1099 | <40 | CM, TM, EM, HLA-DR+, HLA-DR− | 18.5 | EFV/TDF/FTC, ECV | 528 | <40 | Naive, CM/HLA-DR±, TM/ HLA-DR±, EM/HLA-DR± |
| 1292 | M | 49 | >12 | 342 | 4.6 | 3.3a | EFV/FTC/TDF | 746 | <40 | Naive, CM, TM, EM | 7.9 | EFV/TDF/FTC | 677 | <40 | Naive, CM/HLA-DR±, TM/ HLA-DR±, EM/HLA-DR± |
| 2518 | F | 59 | >12 | 70 | 3.5 | 14.8 | TDF, AZT/3TC, NVP | 432 | <40 | Naive, CM, TM, EM, HLA-DR+, HLA-DR− | 18.3 | TDF, AZT/3TC, NVP | 179 | <40 | Naive, CM/HLA-DR±, TM/ HLA-DR±, EM/HLA-DR± |
| 2013 | M | 70 | >12 | 13 | 4.0 | 17.1 | ABC/3TC, RGV | 819 | <40 | HLA-DR−, HLA-DR+ | 21.2 | ABC/TCV/3TC | 530 | <40 | Naive, CM/HLA-DR±, TM/ HLA-DR±, EM/HLA-DR± |
| 2303 | M | 44 | <6 | 478 | 4.2 | 4.7a | EFV/FTC/TDF | 606 | <40 | Naive, CM, TM, EM | 8.9 | ABC/TCV/3TC | 880 | <40 | Naive, CM/HLA-DR±, TM/ HLA-DR±, EM/HLA-DR± |
| 2302 | M | 32 | <6 | 391 | 4.9 | 4.6a | FPV, RTV, TDF/FTC | 696 | <40 | Naive, CM, TM, EM | 9.5 | EGV/TAF/FTC/COBI | 654 | <40 | Naive, CM/HLA-DR±, TM/ HLA-DR±, EM/HLA-DR± |
| 2286 | M | 52 | <6 | 165 | 5.4 | 9.1a | EFV/FTC/TDF | 381 | <40 | Naive, CM, TM, EM | 14.5 | RPV/TDF/FTC | 400 | <40 | Naive, CM/HLA-DR±, TM/ HLA-DR±, EM/HLA-DR± |
Abbreviations: 3TC, lamivudine; ABC, abacavir; AZT, zidovudine; CM, central memory; COBI, cobicistat; DRV, darunavir; ECV, entecavir; EFV, efavirenz; EGV, elvitegravir; EM, effector memory; ETR, etravirine; FPV, fosamprenavir; FTC, emtricitabine; MVC, maraviroc; NVP, nevirapine; RPV, rilpivirine; RTG, raltegravir; RTV, ritonavir; TAF, tenofovir alafenamide; TCV, dolutegravir; TDF, tenofovir disoproxil fumarate; TM, transitional memory.
aFor 4 participants the time to viral suppression (<40 copies/mL plasma) after ART administration was unknown at time point 1, so for time point 1 the time listed is years on ART.